HIV, Gilead and PrEP
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I success
Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) following the success of a Phase I study. The Phase I trial investigated two single 5,
Interesting Engineering on MSN14h
Revolutionary HIV injection could offer a full year of protection in just one doseA groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...
An annual jab to protect against HIV “shows potential”, according to an early study. Millions of people around the world are ...
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...
Dr. Maya Green discusses HIV prevention, addressing racial disparities in healthcare, and the powerful impact of stigma on ...
We can now prevent HIV transmissions and deaths — progress impossible without investments from the U.S. government ...
News Medical on MSN2h
Gaps in HPV cancer screening and prevention identified for people living with HIVA new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.
A revolutionary advancement in HIV prevention technology stands at a critical crossroads as recent policy decisions threaten ...
Utilizing syringe service programs to provide comprehensive PrEP care shows promise for encouraging more people who inject ...
Prevalence varies by region and is impacted by social stigma, access to preventive medicine and a lack of HIV/AIDS education, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback